{
    "clinical_study": {
        "@rank": "31740", 
        "acronym": "HyBraFi", 
        "arm_group": [
            {
                "arm_group_label": "Hypofraction", 
                "arm_group_type": "Experimental", 
                "description": "Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days)."
            }, 
            {
                "arm_group_label": "Standard", 
                "arm_group_type": "Active Comparator", 
                "description": "Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare toxicities between 2 external beam radiation\n      fractionation schemes plus a brachytherapy boost for prostate cancer. Our current standard\n      use a 2 Gy per fraction schedule which is compare to the experimental hypofractionated 3 Gy\n      per day approach with neo adjuvant hormonal therapy. It will demonstrate the feasibility and\n      safety of such a treatment regimen in prostate cancer. It may also set base for a larger\n      randomized trial."
        }, 
        "brief_title": "Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment", 
        "completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "30 patients with intermediate / extensive low risk (all core biopsies involvements > 50%)\n      prostate cancer (not necessitating to treat the nodal regions) will be included in this\n      study.  Patient stage T1 - T2, Gleason score \u2264 7, prostate-specific antigen (PSA) \u2264 20 will\n      be considered.\n\n      Fiducial gold markers will be introduced in the prostate 1-week before the CT planning. 36\n      gray (Gy) in 12 fractions using intensity-modulated radiation therapy (IMRT) will be\n      administered to the prostate (margins of 0,5cm) +/- first centimeter of the seminal\n      vesicles.\n\n      Brachytherapy boost (15 Gy x 1) dosimetric parameters should respect our current standard\n      (Prostate V100 > 90% and V150 \u2264 40%, V200 \u2264 15%, Urethra V125 \u2264 1 cc, Rectum V75 \u2264 1cc,\n      Bladder V75 \u2264 1cc). Short course (4 months) hormonal therapy (Degarelix) will be\n      administered to the patient based upon recommended litterature11, 12.\n\n      Genitourinary (GU), GI and Sexual toxicity will be self reported. QOL questionnaires will be\n      given to the patients to be answered.  Results will be monitored and compared to our\n      currently used standard fractionation regiment.\n\n      Follow-up will be scheduled 6 weeks after the implant and every 4 months for the first year,\n      every 6 months for the second year 2 to 5, and on a yearly basis after 5 years. PSA &\n      testosterone tests will be done every 3 months for the first 3 years, every 6 months on\n      years 4 and 5, and yearly thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  30 patients\n\n          -  intermediate / extensive low risk (all core biopsies involvements > 50%)\n\n          -  prostate cancer (not necessitating to treat the nodal regions)\n\n          -  Patient stage T1 - T2,\n\n          -  Gleason score \u2264 7,\n\n          -  PSA \u2264 20 will be considered\n\n        Exclusion Criteria:\n\n          -  patient unfit for biopsy or brachytherapy\n\n          -  high or low risk prostate cancer"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01851018", 
            "org_study_id": "H12-03-90", 
            "secondary_id": "HYBRAFI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hypofraction", 
                "description": "Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).", 
                "intervention_name": "Hypofraction", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Standard", 
                "description": "Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists", 
                "intervention_name": "Standard", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostate cancer", 
            "brachytherapy", 
            "hypofractionated radiation therapy", 
            "hormonal therapy"
        ], 
        "lastchanged_date": "May 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1R 2J6"
                    }, 
                    "name": "CHUQ L'Hotel-Dieu de Quebec"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1R 2J6"
                    }, 
                    "name": "CHUdeQuebec"
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Match Pair Analysis Study, Comparing Toxicities Between 2 Treatment Regiments Including Neo-adjuvant Hormonal Therapy Plus Hypofractionated RT With HDR Brachytherapy Boost Compare to Our Current Clinical Standard Approach at CHU de Quebec", 
        "overall_official": {
            "affiliation": "CHUQ L'Hotel Dieu de Quebec", 
            "last_name": "Andre-Guy Martin, MD MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Public Health Agency of Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Comparison of the patient reported IPSS scores through the follow-up between each treatment group.", 
                "measure": "Evaluate and compare toxicity changes through follow-up between our study population and a reference group in regards to Median international prostate symptoms scores (IPSS).", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks post-implant, and at 4,8,12 months"
            }, 
            {
                "description": "Comparison of the patient reported Gastro-intestinal toxicity scores through the follow-up between each treatment group.", 
                "measure": "Evaluate and compare toxicity changes through follow-up between our study population and a reference group in regards to gastro-intestinal (GI) toxicity score.", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks post-implant, and at 4,8,12 months"
            }, 
            {
                "description": "Comparison of the patient reported Sexual toxicity (EPIC or SHIM) scores through the follow-up between each treatment group.", 
                "measure": "Evaluate and compare toxicity changes through follow-up between our study population and a reference group in regards to Sexual toxicity (EPIC or SHIM) score.", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks post-implant, and at 4,8,12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01851018"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre Hospitalier Universitaire de Qu\u00e9bec, CHU de Qu\u00e9bec", 
            "investigator_full_name": "Andr\u00e9-Guy Martin", 
            "investigator_title": "Andr\u00e9-Guy Martin MD MSC FRCP(C) Radio-oncologue, Curieth\u00e9rapeute Professeur Associ\u00e9, Universit\u00e9 Laval, L'H\u00f4tel-Dieu de Qu\u00e9bec du CHUQ", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "biochemical disease free survival (Phoenix definition)", 
            "measure": "Evaluate and compare biochemical disease free survival being non inferior to comparative cohort", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "source": "Centre Hospitalier Universitaire de Qu\u00e9bec, CHU de Qu\u00e9bec", 
        "sponsors": {
            "collaborator": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de Qu\u00e9bec, CHU de Qu\u00e9bec", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}